Vivani Medical
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 44
- Market Cap
- $74.5M
- Website
- http://www.vivani.com
- Introduction
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
- Conditions
- Overweight and ObesityType2diabetes
- Interventions
- Drug: Semaglutide, 1.0 mg/mLCombination Product: Exenatide Implant
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Vivani Medical, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05670379
- Locations
- 🇦🇺
CMax, Adelaide, Australia
News
Vivani Medical Achieves First GLP-1 Implant and Full Enrollment in LIBERATE-1 Trial for Obesity Treatment
Vivani Medical has successfully administered its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial, marking a significant advancement in addressing medication adherence challenges in metabolic diseases.
Vivani Medical to Spin Off Cortigent Neurostimulation Business as Independent Public Company
Vivani Medical plans to spin off its Cortigent neurostimulation division as an independent Nasdaq-listed company by Q3 2025, allowing each entity to focus on their distinct therapeutic areas.
Vivani Medical's Innovative GLP-1 Obesity Implant Garners Buy Ratings
Vivani Medical is developing the NPM-115 implant, a 6-month duration GLP-1 drug delivery system for obesity treatment, potentially improving patient compliance.
Vivani Medical's GLP-1 Implant for Obesity and Overweight Approved for Human Trials in Australia
Vivani Medical received approval to begin its first-in-human clinical trial in Australia for its subdermal GLP-1 implant, NPM-115, designed for obesity and overweight individuals.